<DOC>
	<DOC>NCT00293254</DOC>
	<brief_summary>This study will investigate the safety and efficacy of raltegravir as a therapy for Human Immunodeficiency Virus (HIV)-infected patients failing current therapy with 3-class antiviral resistance.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of Raltegravir (MK0518) in HIV-Infected Patients Failing Current Antiretroviral Therapies (0518-019)</brief_title>
	<detailed_description>The primary double-blind study of raltegravir versus placebo was extended to 156 weeks and was followed by an open-label raltegravir phase in which continuing participants from both the raltegravir and placebo groups received open-label raltegravir for an additional 84 weeks for a maximum duration of up to 240 weeks. Participants who had viral failure after Week 16 may have received open-label raltegravir until Week 240.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patient must be HIV positive with HIV RNA values that are within ranges required by the study Patient must have documented failure of certain antiretroviral therapy Patient must be on the same antiretroviral therapy for at least the past two months Patient less than 16 years old Additional study criteria will be discussed and identified by the study doctor</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Treatment Experienced</keyword>
</DOC>